Novo Nordisk Stock: Buy or Sell? | NVO Stock Analysis

SUMMARY

Parkev Tatevosian, CFA, provides a comprehensive analysis of Novo Nordisk's recent financial performance and future outlook, focusing on the company's GLP-1 product sales, profitability, and valuation. He maintains a buy rating on the stock despite its recent decline, citing strong fundamentals and undervaluation, while noting a personal preference for Eli Lilly.

MAIN POINTS

• Novo Nordisk's GLP-1 product sales have significantly increased revenue, but the stock is down 8% year-to-date in 2026. [0:00]
• Future revenue growth is expected to slow, with a projected decline in 2026 followed by modest increases in 2027 and 2028, while profitability remains strong. [1:00]
• The company's ability to innovate and develop new treatments is highlighted as a key investment consideration, despite declining returns on invested capital. [2:00]
• Return on invested capital has dropped from above 80% a decade ago to 37%, raising concerns about long-term value creation. [3:00]
• Novo Nordisk's forward price-to-earnings ratio is near historical lows, and revised free cash flow estimates still indicate the stock is undervalued. [4:01]
• A fair value estimate of $123 per share is calculated, well above the current market price of $47, leading to a reiterated buy rating, though Eli Lilly is preferred. [5:00]

DETAILED ANALYSIS

Novo Nordisk has experienced a dramatic increase in revenue over the past several years, primarily driven by the success of its GLP-1 products, which are used for weight loss and diabetes management. Revenues have nearly tripled since 2017, reaching over $51.5 billion in the trailing twelve months. Despite this growth, the company's stock price has declined by 8% year-to-date in 2026, reflecting investor concerns about the sustainability of this growth.

Forward-looking estimates suggest a 6.3% revenue decline in 2026, followed by modest growth of 2.5% in 2027 and 6.4% in 2028, indicating that the explosive phase of GLP-1-driven expansion may be over.

Novo Nordisk continues to demonstrate robust profitability, with operating profit margins consistently above 40% and reaching 45.4% in the most recent period. However, there is a notable downward trend in the company's return on invested capital (ROIC), which has fallen from over 80% a decade ago to 37% currently. While this level remains strong for a pharmaceutical company, the persistent decline raises concerns about the company's ability to generate shareholder value in the future, especially as research and development investments may not yield the same returns as in the past.

Valuation metrics suggest the stock is undervalued. The forward price-to-earnings ratio stands at 14.14, near its lowest level since 2023, reflecting tempered investor enthusiasm as GLP-1 sales plateau. Updated discounted cash flow analysis, incorporating a $500 million annual reduction in free cash flow estimates for 2026 and 2027, still yields a fair value estimate of $123 per share, significantly above the current market price of $47.

This supports the case for maintaining a buy rating, despite recent underperformance. Nonetheless, among peers, Eli Lilly is identified as a more attractive alternative, though Novo Nordisk remains a compelling opportunity based on current fundamentals and valuation.

LINKS

• YouTube channel membership for exclusive perks and early access.
• Special offer for The Motley Fool Stock Advisor.
• Parkev Tatevosian's book on a 6-step investing framework.
• Fiscal.ai investment research tool with a viewer discount.
• Webull sign-up link for bonus shares and commission-free investing.
• Subscribe to Parkev Tatevosian's free monthly Substack newsletter.

KEYWORDS